Invention Grant
- Patent Title: CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
-
Application No.: US16048677Application Date: 2018-07-30
-
Publication No.: US11407721B2Publication Date: 2022-08-09
- Inventor: Michael D. Bartberger , Hilary Plake Beck , Michael R. Degraffenreid , Brian M. Fox , Felix Gonzalez Lopez De Turiso , Lisa D. Julian , Frank Kayser , Julio C. Medina , Steven H. Olson , Yosup Rew , Philip M. Roveto , Daqing Sun , Xuelei Yan
- Applicant: AMGEN INC.
- Applicant Address: US CA Thousand Oaks
- Assignee: AMGEN INC.
- Current Assignee: AMGEN INC.
- Current Assignee Address: US CA Thousand Oaks
- Agent Markus Bergauer
- Main IPC: C07D265/32
- IPC: C07D265/32 ; C07D413/06 ; C07D487/04 ; C07D279/12 ; C07D413/04
Abstract:
The present invention provides MDM2 inhibitor compounds of Formula I, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
Public/Granted literature
- US20180354918A1 CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER Public/Granted day:2018-12-13
Information query
